A Phase 2/3, multicenter, randomized open-label study of zanzalintinib vs everolimus in participants with previously treated, unresectable, locally advanced or metastatic neuroendocrine tumors
Clinical Trial Grant
Awarded By
Exelixis, Inc
Start Date
August 22, 2025
End Date
September 4, 2030
Awarded By
Exelixis, Inc
Start Date
August 22, 2025
End Date
September 4, 2030